Living With MS

Discussing all aspects of Multiple Sclerosis, various treatments, including accurate information regarding Tysabri.

Thursday, May 03, 2007




My Tysabri Diary...Can I Get A WoooHooo? Good News!
:D

Hi all, new data from the TOUCH Prescribing Program™ and TYGRIS (TYsabri Global ObseRvation Program In Safety) safety study confirms the safety profile from previous clinical studies of TYSABRI® (natalizumab), and according to data available to the companies as of April 23, 2007, there have been no new reports of confirmed cases of progressive multifocal leukoencephalopathy (PML) or other serious opportunistic infections (OIs). The data confirm the safety profile from previous clinical studies of TYSABRI and will continue to expand the knowledge of the long-term safety and tolerability of TYSABRI.

Also presented at the 59th annual meeting of the American Academy of Neurology in Boston, MA were extension study data that showed that TYSABRI has a sustained treatment effect on clinical relapses and the risk of disability progression in multiple sclerosis (MS) patients treated for up to three years. The companies recently reported that as of mid-April 2007 approximately 12,500 patients have been prescribed TYSABRI worldwide. The companies estimate that in both commercial use and clinical trials, there are currently over 10,000 patients on TYSABRI therapy worldwide.

Here is a link for the full data released: Data Presented at the American Academy of Neurology's Annual Meeting Provide Update on Utilization and Safety of TYSABRI® in Patients with Multiple Sclerosis.....Additional Data From Extension Study Presented Show TYSABRI Benefit is Sustained Over Three Years http://www.elan.com/News/full.asp?ID=995005

I can't stay, but wanted to post the above fantastic news as it sure beats crying my eyes out (today's date 5/3, would have been my 27th Wedding Anniversary) ... good triumphs over bad again - wooohoooooo!

(((((((hugs everyone)))))))) :D

Love, Lauren
A very proud member of www.MSpatientsforchoice.org

0 Comments:

Post a Comment

Links to this post:

Create a Link

<< Home